Published by Iain Gilbert on 27th September 2017
(ShareCast News) - Synairgen announced on Wednesday it had narrowed its operating loss for the six months leading to 30 June thanks to "excellent progress" made in the development of its Lysyl Oxidase-Like 2 (LOXL2) enzyme inhibitor, and its AZD9412 (SNG001) programme.